A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Sep 2017
At a glance
- Drugs Binimetinib (Primary) ; Carboplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 20 Sep 2017 Planned End Date changed from 1 Apr 2018 to 1 Apr 2019.
- 20 Sep 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.
- 20 Sep 2017 Planned initiation date changed from 1 Mar 2017 to 1 Jan 2018.